For the quarter ended December 2024, Boston Scientific (BSX) reported revenue of $4.56 billion, up 22.4% over the same period last year. EPS came in at $0.70, compared to $0.55 in the year-ago quarter.
The reported revenue represents a surprise of +3.52% over the Zacks Consensus Estimate of $4.41 billion. With the consensus EPS estimate being $0.65, the EPS surprise was +7.69%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- U.S. $2.89 billion versus $2.72 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +30.7% change.
- Geographic Revenue- Rest of the World: $1.67 billion compared to the $1.70 billion average estimate based on three analysts. The reported number represents a change of +10.2% year over year.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- United States: $349 million versus the two-analyst average estimate of $347.87 million. The reported number represents a year-over-year change of 0%.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- International: $218 million versus the two-analyst average estimate of $215.44 million. The reported number represents a year-over-year change of +6.9%.
- Net Sales- MedSurg- Worldwide: $1.62 billion versus the six-analyst average estimate of $1.56 billion. The reported number represents a year-over-year change of +12.4%.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $2.30 billion compared to the $2.22 billion average estimate based on five analysts. The reported number represents a change of +31.2% year over year.
- Net Sales- MedSurg- Urology- Worldwide: $630 million compared to the $583.73 million average estimate based on five analysts. The reported number represents a change of +19.5% year over year.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $645 million compared to the $628.06 million average estimate based on five analysts. The reported number represents a change of +21% year over year.
- Net Sales- MedSurg- Endoscopy- Worldwide: $690 million versus $687.90 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +7% change.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $299 million compared to the $282.68 million average estimate based on five analysts. The reported number represents a change of +11.2% year over year.
- Net Sales- Cardiovascular- Interventional Cardiology Therapies- Worldwide: $668 million versus the four-analyst average estimate of $672.18 million. The reported number represents a year-over-year change of +8.8%.
- Net Sales- Cardiovascular- Watchman- Worldwide: $413 million versus $405.85 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +19.7% change.
Shares of Boston Scientific have returned +12.6% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Boston Scientific Corporation (BSX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
